In addition, the Y537S and D538G ESR1 mutations are heterozygous in the engineered mutant cell lines, more accurately reflecting the natural history of these mutations in refractory breast cancers [10] and adding to the clinical relevance of these in vivo models. This evidence concerns the gene ESR1 and breast carcinoma.